MAPS Act

H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. H.R. 8339: Drug Origin Transparency Act to amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting H.R. 5526/S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521/S. 4440: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses. H.R. 8839/S. 5052: Lainie Jones Comprehensive Cancer Survivorship Act of 2026 to address the health of cancer survivors.

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act (CLEAR LABELS) Act: Provisions regarding drug labeling.

Client expense: $130,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1784, H.R. 4191 - Mapping America's Pharmaceutical Supply (MAPS) Act - Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act (CLEAR LABELS) Act: Provisions regarding drug labeling. Issues related to strengthening the resiliency of the U.S. medical supply chain.

Client expense: $120,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE, White House Office

Childrens Hospitals Graduate Medical Education (CHGME) program - Urged increased funding in FY 2027 to fund CHGME with the same priority as other federal physician training programs Continued healthcare access - Advocated for a more resilient healthcare infrastructure and policies that provide the staffing and technological infrastructure necessary to maintain essential services Continued monitoring and encouraged passage of the Biosimilar Red Tape Elimination Act (S.1954) Continued monitoring and encouraged passage of the Improving Seniors' Timely Access to Care Act (H.R. 3514/S.1816) Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279) Continued monitoring and encouraged passage of the Protecting Health Care and Lowering Costs Act (S.2556) Continued monitoring and encouraged passage of the Resident Physician Shortage Reduction Act of 2025 (S.2439/H.R.3890/H.R.4731) Continued monitoring and encouraged passage of the Save Healthcare Workers Act (S.1600/H.R.3178). Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory. Encouraged improved stakeholder communication and increased notification by manufacturers for surges in demand Endorsed and encouraged passage of the Drug Origin Transparency Act of 2026 (HR.8339) Hospital Data and Analytics - Provided education and information on the types of clinical, operational, financial and quality data hospitals collect and monitor to improve patient care. Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations (GPOs) provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs. Supply Assurance - Responded to a Senate Special Committee on Aging inquiry on vulnerabilities in the U.S. pharmaceutical supply chain highlighting the work done by GPOs to improve supply chain resiliency and encouraging additional healthcare supply chain visibility. Urged passage of legislation to reauthorize The Pandemic and All-Hazards Preparedness Act (PAHPA) Telehealth - Encouraged the adoption of additional permanent telehealth policies to extend certain telemedicine flexibilities beyond their current expiration date. United States Core Data for Interoperability Draft Version 7 - Respond to the Office of the National Coordinator for Health Information Technology Policy (ONC) on issues raised in Standards Bulletin 2026-1 (SB26-1) and offered comments to constructively improve certain data elements of Draft USCDI v7. Offered recommendations for future iterations of USCDI standards. Workforce - Advocated for strengthening the health workforce and preventing workforce shortages through policies that support education, training, recruitment and retention efforts.

Client expense: $320,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act (identical legislation); Reauthorization of the Protecting Americans from All-Hazards Preparedness Act (PAHPA) (formerly Pandemics and All-Hazards Preparedness Act).

Client expense: $370,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act (identical legislation); Reauthorization of the Protecting Americans from All-Hazards Preparedness Act (PAHPA) (formerly Pandemics and All-Hazards Preparedness Act).

Client expense: $370,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE

Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to H.R. 8800/S. 4784 - National Defense Authorization Act for Fiscal Year 2027; Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. H.R. 8339: Drug Origin Transparency Act to amend the Federal Food, Drug, and Cosmetic Act to enhance drug manufacturing amount information reporting H.R. 5526/S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521/S. 4440: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses. H.R. 8839: Lainie Jones Comprehensive Cancer Survivorship Act of 2026 to address the health of cancer survivors.

Client expense: $480,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain security and resilience and drug shortages. S. 3788 - Consumer Labeling for Enhanced API Reporting and Legitimate Accountability for Base Entity Listings Act (CLEAR LABELS) Act: Provisions regarding drug labeling.

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Continued healthcare access - Advocated for a more resilient healthcare infrastructure and policies that provide the staffing and technological infrastructure necessary to maintain essential services Continued monitoring and encouraged passage of the Biosimilar Red Tape Elimination Act (S.1954) Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279) Continued monitoring and encouraged passage of the Protecting Health Care and Lowering Costs Act (S.2556) Continued monitoring and encouraged passage of the Resident Physician Shortage Reduction Act of 2025 (S.2439/H.R.3890/H.R.4731) Continued monitoring and encouraged passage of the Save Healthcare Workers Act (S.1600/H.R.3178). Draft Guidance for Industry, Scientific Considerations in Demonstrating Biosimilarity to a Reference Product: Updated Recommendations for Assessing the Need for Comparative Efficacy Studies (Docket No. FDA-2011-D-0605) - Urging FDA to streamline biosimilar approval for increased patient access to cost-effective treatment alternatives Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory. Encouraged improved stakeholder communication and increased notification by manufacturers for surges in demand Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations (GPOs) provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs. Monitored development and introduction of the Drug Origin Transparency Act of 2025 (HR.8339) Monitored development and passage of the Consolidated Appropriations Act, 2026 (H.R. 7148) Payer-mandated White Bagging - Urged support for policy updates related to payer-mandated white bagging for medications

Client expense: $320,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Issues related to the Consolidated Appropriations Act, 2026 (PL 119-75); Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act (identical legislation); Reauthorization of the Protecting Americans from All-Hazards Preparedness Act (PAHPA) (formerly Pandemics and All-Hazards Preparedness Act).

Client expense: $400,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; H.R. 4191, Mapping America's Pharmaceutical Supply (MAPS) Act, (identical legislation); S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act (identical legislation); Reauthorization of the Protecting Americans from All-Hazards Preparedness Act (PAHPA) (formerly Pandemics and All-Hazards Preparedness Act).

Client expense: $400,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), Office of Management & Budget (OMB), SENATE

-Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. -Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. -Support for the Drug Shortages Prevention Act (S 2665), which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages -Support for the reintroduction of the following bill from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications -Comments in response to the notice of proposed rulemaking (ANPRM) Ensuring Safety Through Domestic Security With Made in America Personal Protective Equipment (PPE) and Essential Medicine Procurement by Medicare Participating Hospitals. -Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP). -Support for FY 2027 appropriations for the Dr. Lorna Breen Health Care Provider Protection Act. -Support for the Alternatives to Prevent Addiction in the Nation Act (H.R. 1227), which would reduce cost-sharing and prohibits the imposition of certain utilization requirements under the Medicare prescription drug benefit for certain non-opioid pain management drugs. -Urging CMS to communicate to Part D plan sponsors about the clinical importance of FDA-approved, clinically appropriate non-opioid acute pain treatment options and encourage appropriate formulary coverage ensuring beneficiary access to such approaches.

Client expense: $50,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE

S. 1040, the Drug Competition Enhancement Act. S. 1041, the Affordable Prescriptions for Patients Act. S. 2620, the Reforming Evergreening and Manipulation that Extends Drug Years Act or the REMEDY Act. S. 2658, the Medication Affordability and Patent Integrity Act. S. 1095, the Stop Significant and Time-wasting Abuse Limiting Legitimate Innovation of New Generics (Stop STALLING) Act. S. 1096, the Preserve Access to Affordable Generics and Biosimilars Act. S. 1784/H.R. 4191, the Mapping America's Pharmaceutical Supply Act or the MAPS Act. No bill number. Lifetime prescription drug price increases. No bill number. Discussed Medicare drug price negotiation. No bill number. Discussed Medicare Part D. No bill number. Discussed international reference pricing. No bill number. Discussed prescription drug supply chain vulnerabilities. No bill number. Discussed Most Favored Nation prescription drug model and GLOBE model. No bill number. Discussed Medicare Part D/ Most Favored Nation prescription drug model, GUARD. No bill number. Discussed pharmacy benefit manager reforms. No bill number. Discussed proposed Policy and Technical Changes to the Medicare Advantage Program, Medicare Prescription Drug Benefit Program, and Medicare Cost Plan Program. No bill number. Discussed prescription drugs.

Client expense: $3,830,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation). Issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain, including support for the Mapping Americas Pharmaceutical Supply (MAPS) Act (S. 1784/S. Amdt. 3753). Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). Provisions related to site neutral payments (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). Issues related to protecting federal student loan programs, including the Grad PLUS program (generally, no specific legislation). Issues related to direct-to-consumer (DTC) prescription drug advertising (generally, no specific legislation). Issues related to funding of FDA and CDC (generally, no specific legislation).

Client expense: $240,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Lobbied in favor of reform to country of origin packaging on pharmaceutical drugs. S. 1891 PILLS Act S.1784 MAPS Act

Client expense: Not reported · Firm income: $20,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 1262/S. 932: Mikaela Naylon Give Kids a Chance Act of 2025 - To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes. HR 929/S.266: Dr. Lorna Breen Health Care Provider Protection Reauthorization Act - To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, and for other purposes. H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses.

Client expense: $210,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

340B Drug Pricing Program - Continued to urge action to ensure covered entities have access to 340B discounted prices through contract pharmacies. Highlighted critical importance of the 340B program for hospitals. Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory. Encouraged improved stakeholder communication and increased notification by manufacturers for a surges in demand Continued monitoring and encouraged passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Continued monitoring and encouraged passage of the Biosimilar Red Tape Elimination Act (S.1954) Continued monitoring and encouraged passage of the Resident Physician Shortage Reduction Act of 2025 (S.2439/H.R.3890/H.R.4731) Continued monitoring and encouraged passage of the Protect Medicaid and Rural Hospitals Act (S.2279) Continued monitoring and encouraged passage of the Protecting Health Care and Lowering Costs Act (S.2556) Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs. Responded to Senate Aging Committee inquiry on role of group purchasing organizations in the drug supply chain. Mental and Behavioral Health - Highlighted the need for legislation to address significant challenges to mental and behavioral health treatment, including increased demand for services, limited access to treatment, and clinician shortages. Monitored development and passage of the Continuing Appropriations, Agriculture, Legislative Branch, Military Construction and Veterans Affairs, and Extensions Act, 2026 (H.R. 5371) Non-medical drivers of health outcomes - Encouraged Congress and agencies to ensure tools like the Vizient Vulnerability Index are being utilized to understand data about disparities in health. Highlighted opportunities for the increased use of secondary health data in a clinical setting. Payer-mandated White Bagging - Urged support for policy updates related to payer-mandated white bagging for medications Rural healthcare - Advocated for policies and initiatives that address the challenges of rural communities by promoting access to care and strengthening healthcare infrastructure Telehealth - Continued to advocate for the adoption of permanent telehealth policies to extend flexibilities beyond the current expiration date. Workforce - Advocated for strengthening the health workforce through policies that support education, training, recruitment, and retention efforts. Continued monitoring and encouraged passage of the Save Healthcare Workers Act (S.1600/H.R.3178).

Client expense: $320,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 43: Skinny Labels, Big Savings Act S. 708: RESTORE Patent Rights Act of 2025 S. 1040: Drug Competition Enhancement Act S. 1041: Affordable Prescriptions for Patients Act S. 1095: Stop STALLING Act S. 1096: Preserve Access to Affordable Generics and Biosimilars Act S. 1097: Interagency Patent Coordination and Improvement Act of 2025 S. 1302: Increasing Transparency in Generic Drug Application Act S. 1546: Patent Eligibility Restoration Act of 2025 (PERA) S. 1553: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) S. 1784 MAPS Act S. 2276: Eliminating Thickets to Increase Competition Act (ETHIC Act) S. 2620: REMEDY Act S. 2658: Medication Affordability and Patent Integrity Act H.R. 890: Stopping Pharmas Ripoffs and Drug Savings For All Act H.R. 1574: RESTORE Patent Rights Act of 2025 H.R. 3152: Patent Eligibility Restoration Act of 2025 (PERA) H.R. 3160: Promoting and Respecting Economically Vital American Innovation Leadership Act (PREVAIL Act) H.R. 3269: Eliminating Thickets to Increase Competition Act (ETHIC Act) H.R. 4570: Interagency Patent Coordination and Improvement Act of 2025 H.R. 6485: Skinny Labels, Big Savings Act Biopharmaceutical innovation policy issues Bayh-Dole march-in rights policy issues Patent thicket policy issues AI patent policy issues Patent eligibility policy issues Post-grant proceeding policy issues Patent submission policy issues Patent fee policy issues

Client expense: $810,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Patent & Trademark Office (PTO), SENATE

H.R. 4581 / S.2372, 340B PATIENTS Act, all provisions; H.R. 3178 / S. 1600, The Save Healthcare Workers Act, all provisions; H.R. 929 / S. 266, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, all provisions; H.R. 1585 / S. 709, Conrad State 30 and Physician Access Reauthorization Act, all provisions; S. 1874, Title VIII Nursing Workforce Reauthorization Act, all provisions; S. 1784 / H.R. 4191, The Mapping America's Pharmaceutical Supply (MAPS) Act, all provisions; H.R. 5283 / S. 2759, Healthcare Workforce Resilience Act, all provisions; S. 2062, The Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, all provisions; H.R. 5256, 340B Access Act, all provisions; S. 1929, SEPSIS Act, all provisions; S. 2355 / H.R. 5582, Patients Deserve Price Tags Act, all provisions; S. 1868, the Critical Access for Veterans Care Act, all provisions; S. 3435 / H.R. 6607, The Future Advancement of Academic Nursing, all provisions; DRAFT, Right to Re-Enroll Act of 2026, Issues related to the right of patients to use a special enrollment period if their providers are no longer in-network during the plan year; DRAFT, Issues related to how the Rural Health Transformation Fund allocates funding; S. 3097, Health Information Privacy Reform Act, all provisions; S. 2834 / H.R. 5439, Medically Tailored Home-Delivered Meals Program Pilot Act, all provisions; DRAFT, Issues pertaining to nursing school faculty workforce development; DRAFT, WELLS Act, Issues pertaining to maternal health; S. 3033, Improving Access to Care for Rural Veterans Act , all provisions; H.R. 6445/S. 3364, Fast Track Healthcare Apprenticeships Act, all provisions; H.R. 6010, The Fix it Act, all provisions; H.R. 6538 / S. 3264, The More Affordable Care Act, all provisions; Federal Trade Commission, Employer noncompete agreements- RFI, Comments on employer noncompete agreements; Office of Science and Technology Policy (OSTP) [White House], RFI regarding regulatory reform on artificial intelligence, Comments on regulatory reform on artificial intelligence; U.S Food & Drug Administration (FDA), RFI on artificial intelligence-enabled medical devices, Comments on artificial intelligence - enabled medical devices; U.S. Department of Education, Forthcoming Implementation of the One Big Beautiful Bill Acts (OBBBA) Definition of Professional Degree Programs, Comments pertaining to the changing definition of professional degree programs and impact to health care workforce; U.S. Department of Commerce, Section 232, Investigation on Medical Devices, Comments on impact of future tariffs on medical devices, PPE and other medical goods and impact to hospitals and health systems; Enhanced Premium Tax Credits, Extension of Enhanced Premium Tax Credits; Rural Health Care Access, Issues to protect access to rural health care; 340B Program, Issues pertaining to protecting 340B Program, including 340B Rebate Model Pilot Program; Maternal and Child Health, Access to maternal and child health care and addressing related workforce shortages, conditions of participation (COP), funding priorities; Behavioral Health, Issues related to expanding access to care and reducing regulatory barriers; Workforce, Issues pertaining to workforce development grants, supporting health care workforce, changing definitions of professional degree programs; Health Plan Accountability, Issues specific to prior authorization, patient access to care, adequate provider networks, inappropriate denials, reducing account receivables, prompt pay, No Surprises Act Independent Dispute Resolution process; Health Care Resiliency & Preparedness, Issues pertaining to natural disasters, cyberattacks, cybersecurity workforce, and securing supply chains; Price Transparency, Issues related to hospital price transparency; Tax-exempt status, Issues pertaining to not-for-profit hospitals' tax exempt status and tax-exempt private activity bonds; Immigration, Proposed H1-B Visa Program changes and impact to health care workforce; AI in Healthcare, Issues pertaining to the use of AI in healthcare; Organ procurement and transplantation, Issues pertaining to organ procurement hearings; Veterans affairs issues, Issue pertaining to sterile processing in VA clinics.

Client expense: $6,570,000 · Firm income: Not reported

Government targets: Education, Dept of, Federal Trade Commission (FTC), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Office of Science & Technology Policy (OSTP), SENATE

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Generic Drug Reporting Requirement Language in the Senate NDAA, S.2296 - National Defense Authorization Act for Fiscal Year 2026. S.1071 - National Defense Authorization Act for Fiscal Year 2026. Drug Shortages. H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. Establishment Inspection Reports. S.1414/H.R.__: Expedited Access to Biosimilars Act. S.3469 - BIOSECURE Act of 2025. Quotas on Controlled Substances.

Client expense: $1,150,000 · Firm income: Not reported

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications and the Drug Shortages Prevention Act, which would have required manufacturers to notify the FDA of heightened demand for crucial medicines that could lead to shortages. Encouraging congressional assistance to seek information from the Defense Health Agency, which administers the Tricare program, on the rates used to reimburse participating providers in the TRICARE Active Duty Dental Program (ADDP).

Client expense: $20,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, SENATE

H.R. 6423/S. 864: HELP Copays Act - requires health insurers to count third-party financial assistance toward patients' cost-sharing obligations, including deductibles and copays, for prescription drugs, with changes effective for plan years beginning January 1, 2026. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 1262/S. 932: Give Kids a Chance Act of 2025 - To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes. HR 929/S.266: Dr. Lorna Breen Health Care Provider Protection Reauthorization Act - To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, and for other purposes. H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses.

Client expense: $120,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain security and resilience and drug shortages.

Client expense: $100,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act. (identical legislation)

Client expense: $410,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act. (identical legislation)

Client expense: $410,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE

Issues related to drug pricing, drug shortages, drug importation plans, and the drug supply chain, including support for the Mapping Americas Pharmaceutical Supply (MAPS) Act (S. 1784/S. Amdt. 3753). Issues related to telehealth and pharmacist provision of testing and vaccination (generally, no specific legislation). Patient access to pharmacist provided services for respiratory illnesses, initiation of oral antivirals, buprenorphine, and other pharmacist services authorized under state law (generally, no specific legislation). Issues related to healthcare workforce shortages (generally, no specific legislation). Provisions related to site neutral payments (generally, no specific legislation). The Dr. Lorna Breen Health Care Provider Protection Reauthorization Act (H.R. 929/S. 266), provisions related to supporting health workers mental health and well-being. Issues related to implementation of the Inflation Reduction Act (generally, no specific legislation). Issues related to protecting federal student loan programs, including the Grad PLUS program (generally, no specific legislation). Issues related to direct-to-consumer (DTC) prescription drug advertising (generally, no specific legislation). Issues related to vaccine access and evidence-based resources for patients and pharmacists (generally, no specific legislation).

Client expense: $250,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Issues related to H.R. 5304/S. 2587 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026; Issues related to H.R. 4016/S. 2572 - Department of Defense Appropriations Act, 2026; Issues related to the National Defense Authorization Act for Fiscal Year 2026 (PL 119-60); Issues related to H.R. 4191/S. 1784 - MAPS Act; Issues related to H.R. 3955/S. 2062 - RAPID Reserve Act.

Client expense: Not reported · Firm income: $90,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864, HELP Copays Act - A bill to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes. S. 882, Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Provisions related to the pharmaceutical industry. S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 1302: Increasing Transparency in Generic Drug Applications Act S. 1414: Expedited Acccess to Biosimilars Act S. 1784: MAPS Act S. 1954: Biosimilar Red Tape Elimination Act H.R. 1: One Big Beautiful Bill Act H.R. 946: Orphan Cures Act H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act H.R. 4132: Prescription Information Modernization Act of 2025 HR 6283: Delinking Revenue from Unfair Gouging (DRUG) Act - bill aimed at reforming practices of Pharmacy Benefit Managers (PBMs) by delinking their revenue from the list price of prescription drugs Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues Accelerated approval policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order, Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order, Lowering Drug Prices by Once Again Putting Americans First

Client expense: $1,700,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act. (identical legislation)

Client expense: $420,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act. (identical legislation)

Client expense: $420,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE

S. 1784 - Mapping America's Pharmaceutical Supply (MAPS) Act; H.R. 4191: Provisions regarding supply chain resilience. Issues regarding drug shortages and pharmaceutical supply chain resilience.

Client expense: $80,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Prescription Drug Costs. H.R.1843: To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. S.1302: Increasing Transparency in Generic Drug Applications Act. Generic Drug Reporting Requirement Language in the Senate NDAA, S.2296 - National Defense Authorization Act for Fiscal Year 2026. H.R.1396/S.1891: Producing Incentives for Long-term Production of Lifesaving Supply of Medicine (PILLS) Act. Drug Shortages. H.R.5526/S.1954: Biosimilar Red Tape Elimination Act (BRTEA). H.R.1051: To amend the Federal Food, Drug, and Cosmetic Act to allow for the approval of an abbreviated new drug application submitted by a subsequent applicant in the case of a failure by a first applicant to commence commercial marketing within a certain period, and for other purposes. American Relief Act, 2025 (PL. No: 118-158) as it relates to Patent Thickets and Q1/Q2. H.R.3955/S.2062: RAPID Reserve Act. H.R.4191/S.1784: Mapping Americas Pharmaceutical Supply (MAPS) Act. H.R.4132/S.2027: Prescription Information Modernization Act of 2025. Establishment Inspection Reports. S.1414/H.R._: Expedited Access to Biosimilars Act.

Client expense: $640,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Congressional Budget Office (CBO), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Economic Council (NEC), SENATE, White House Office

H.R. 4581 / S.2372, 340B PATIENTS Act, all provisions; H.R. 3178 / S. 1600, The Save Healthcare Workers Act, all provisions; H.R. 929 / S. 266, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, all provisions; H.R. 1585 / S. 709, Conrad State 30 and Physician Access Reauthorization Act, all provisions; S. 1874Title VIII Nursing Workforce Reauthorization Act, all provisions; S. 1784 / H.R. 4191, The Mapping America's Pharmaceutical Supply (MAPS) Act, all provisions; H.R. 5283 / S. 2759, Healthcare Workforce Resilience Act, all provisions; H.R. 5428, Medical Student Education Authorization Act, all provisions; S. 1929, SEPSIS Act, all provisions; H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025, all provisions; S. 2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID) Reserve Act, all provisions; S. 921, Tyler's Law, all provisions; H.R. 3482, Veterans Community Care Scheduling Improvement Act, all provisions; HR 3483, Forcing Real Accountability for Unlawful Distributions Act (FRAUD) Act of 2025, all provisions; HR 3494, VA Hospital Inventory Management System Authorization Act, all provisions; H.R. 3413, Physician and Patient Safety Act, all provisions; H.R. 2936, Addressing Boarding and Crowding in the Emergency Department, all provisions; Department of Health & Human Services (HHS), AHRQ 2025-001 Request for Information; Ensuring Lawful Regulation and Unleashing Innovation to Make America Healthy Again, Comments on easing administrative burdens and encouraging innovation in health care; Health Resources & Services Administration (HRSA); Health Resources and Services Administration (HRSA), 340B Rebate Model Pilot Program, Comments pertaining to 340B Rebate Model Pilot Program; Enhanced Premium Tax Credits, Extension of Enhanced Premium Tax Credits; Rural Health Care Access, Issues to protect access to rural health care; 340B Program, Issues pertaining to protecting 340B Program, including 340B Rebate Model Pilot Program; Maternal and Child Health, Access to maternal and child health care and addressing related workforce shortages, conditions of participation (COP), funding priorities; Behavioral Health, Issues related to expanding access to care and reducing regulatory barriers; Workforce, Issues pertaining to workforce development grants and supporting health care workforce; Health Plan Accountability, Issues specific to prior authorization, patient access to care, adequate provider networks, inappropriate denials, reducing account receivables, prompt pay; Health Care Resiliency & Preparedness, Issues pertaining to natural disasters, cyberattacks, cybersecurity workforce, and securing supply chains; Price Transparency, Issues related to hospital price transparency; Post Acute Care, Issues pertaining to expanding patients' access and easy regulatory burdens to crucial services provided by Long-term care hospitals, inpatient rehabilitation facilities, skilled nursing facilities, and home health agencies; Tax-exempt status, Issues pertaining to not-for-profit hospitals' tax exempt status and tax-exempt private activity bonds; Immigration, Proposed H1-B Visa Program changes and impact to health care workforce; Organ Procurement, Issues pertaining to organ procurement and transplantation.

Client expense: $5,720,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE

340B Drug Pricing Program - Continued to urge action to ensure covered entities have access to 340B discounted prices through contract pharmacies. Highlighted critical importance of the 340B program for hospitals. 340B Program Notice: Application Process for the 340B Rebate Model Pilot Program (HHS Docket No. HRSA-2025-14619) - Provide feedback to the Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs (OPA) notice and request for comments (RFC) regarding the application process for the 340B Rebate Model Pilot Program Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory. Encouraged improved stakeholder communication and increased notification by manufacturers for a surges in demand Endorsed passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (S.1784/H.R.4191) Endorsed passage of the Biosimilar Red Tape Elimination Act (S.1954) Endorsed passage of the Resident Physician Shortage Reduction Act of 2025 (S.2439/H.R.3890/H.R.4731) Endorsed passage of the Protect Medicaid and Rural Hospitals Act (S.2279) Endorsed passage of the Protecting Health Care and Lowering Costs Act (S.2556) Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs. Hospital Price Transparency - Responded to CMS Hospital Price Transparency Accuracy and Completeness Request for Information (RFI), urge the agency to alleviate excessive administrative burden on providers. Monitored development and passage of the One Big Beautiful Bill Act (H.R.1) Mental and Behavioral Health - Highlighted the need for legislation to address significant challenges to mental and behavioral health treatment, including increased demand for services, limited access to treatment, and clinician shortages. Non-medical drivers of health outcomes - Encouraged Congress and agencies to ensure tools like the Vizient Vulnerability Index are being utilized to understand data about disparities in health. Highlighted opportunities for the increased use of secondary health data in a clinical setting. Payer-mandated White Bagging - Urged support for policy updates related to payer-mandated white bagging for medications Rural healthcare - Advocated for policies and initiatives that address the challenges of rural communities by promoting access to care and strengthening healthcare infrastructure Telehealth - Continued to advocate for the adoption of permanent telehealth policies to extend flexibilities beyond the current expiration date. Ultra-Processed Foods; RFI (Docket No. FDA-2025-N-1793) - Responded to FDA and USDAs request for information encouraging efforts to consider a uniform, science-based definition of UPFs through coordinated federal efforts Workforce - Advocated for strengthening the health workforce through policies that support education, training, recruitment, and retention efforts. Continued monitoring and encouraged passage of the Save Healthcare Workers Act (S.1600/H.R.3178). Hosted congressional briefing educating Senate and House staff on the education and training needs to address healthcare worker shortages, burnout and workplace violence.

Client expense: $320,000 · Firm income: Not reported

Government targets: Agriculture, Dept of (USDA), Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), SENATE

S. 864: HELP Copays Act - To amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes. S. 526: PBM Transparency Act - prevents unfair and deceptive acts or practices and the dissemination of false information related to pharmacy benefit management services for prescription drugs H.R. 1262/S. 932: Give Kids a Chance Act of 2025 - To amend the Federal Food, Drug, and Cosmetic Act with respect to molecularly targeted pediatric cancer investigations, and for other purposes. HR 929/S.266: Dr. Lorna Breen Health Care Provider Protection Reauthorization Act - To reauthorize the Dr. Lorna Breen Health Care Provider Protection Act, and for other purposes. H.R. 4191/S. 1784: MAPS Act - requires federal agencies to regularly update a list of essential medicines, assess and report on supply chain risks, map pharmaceutical supply chains, and enhance coordination and cybersecurity to protect public health and national security. H.R. 3955/S.2062: RAPID Reserve Act - establishes a $500 million program to create and maintain domestic reserves of critical drugs and their ingredients, prioritizing domestic manufacturing and supply chain resilience to prevent shortages during public health emergencies. S. 1954: Biosimilar Red Tape Elimination Act - streamlines the approval process for biosimilar biological products by automatically deeming them interchangeable with reference products, subject to certain exclusivity protections, and requires updated regulatory guidance to reflect these changes. H.R. 4191: To improve coordination of Federal efforts to identify and mitigate health and national security risks through maintaining a list of essential medicines, conducting a risk assessment of essential medicine supply chains, and creating a monitoring system to map essential medicine supply chains using data analytics. H.R. 4101: Cancer Drug Parity Act of 2025 - requires group health plans to provide cost-sharing for oral anticancer drugs that is at least as favorable as for provider-administered anticancer medications, with protections against increased patient costs and a mandated GAO study on the law's impact. H.R. 3521: Clinical Trials Modernization Act - Increase clinical trial participation among underrepresented populations by providing grants, permitting certain participant reimbursements, and offering tax exclusions, while ensuring compliance with existing legal protections. S. 705: Innovation in Pediatric Drugs Act of 2025 - amends existing laws to enhance pediatric cancer research, mandates compliance measures, allocates funding for pediatric studies, and sets guidelines for orphan drugs, with specific timelines for implementation and evaluation. H.R. 5509/S. 2903: Safe Step Act - to require a group health plan or health insurance coverage offered in connection with such a plan to provide an exceptions process for any medication step therapy protocol, and for other purposes. H.R. 4425/S. 2287: Palliative Care and Hospice Education and Training Act - expands federal support for workforce development, education, public awareness, and research in palliative and hospice care, with targeted funding and statutory changes to improve care for patients with serious or life-threatening illnesses. Cures 2.1

Client expense: $110,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1, the One Big Beautiful Bill Act of 2025. No bill number. Discussed drug supply chain and Executive Order on strategic reserve of active pharmaceutical ingredients. S. 2620, the Reforming Evergreening and Manipulation that Extends Drug Years (REMEDY) Act of 2025. S. 1784/H.R. 4191, the Mapping America's Pharmaceutical Supply (MAPS) Act of 2025. S.832/H.R. 1492, the Ensuring Pathways to Innovative Cures (EPIC) Act of 2025. No bill number. Discussed the Medicare drug price negotiation program. No bill number. Discussed pharmacy benefit manager reforms. No bill number. Discussed Most Favored Nation drug pricing proposals.

Client expense: $3,810,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office

Support for the RAPID Reserve Act (S 2062/HR 3955), which aims to address drug shortages by awarding federal contracts to American-based manufacturers of generic drugs to encourage domestic production of these critical medications as well as incentivize them to increase their reserves in preparation for possible future public health threats or supply chain challenges and ramp up their production capacity if necessary to proactively prevent shortages. Support for the Mapping Americas Pharmaceutical Supply or MAPS Act (S 1784/HR 4191), which seeks conduct a risk assessment and supply chain map of all essential medicines to help identify vulnerabilities and potential national security risks. Support for the reintroduction of the following drug and supply bills from the 118th Congress: The Drug Shortages Prevention and Quality Improvement Act, which aimed to implement reimbursement models to incentivize the production of generic injectables and extend expiration dates for lifesaving medications. Suggestions for deregulation within federal healthcare programs, specifically the request to Rescind Limitations on Notice and Consent Waivers for Non-Emergency Services under the No Surprises Act and to Streamline or Eliminate the Merit-based Incentive Payment System (MIPS). Comments to CMS expressing concern about implementation of the Non-Opioids Prevent Addiction in the Nation ("NOPAIN") Act as provided for in the CY 2026 Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems Proposed Rule. Support for HR 4556, the the Protect Our Treatment for Enamel, Erosion, and Tooth Health (TEETH Act), which would require the Environmental Protection Agency (EPA) to commission an independent, rapid-response evidence review from the National Academies of Sciences, Engineering, and Medicine before proposing updates to drinking water regulations that affect community water fluoridation.

Client expense: $20,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

S. 652: Protecting Patients from Deceptive Drug Ads Act S. 832: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 S. 864, HELP Copays Act - A bill to amend title XXVII of the Public Health Service Act to apply financial assistance towards the cost-sharing requirements of health insurance plans, and for other purposes. S. 882, Patients Before Middlemen Act, and other legislation related to pharmacy benefit manager (PBM) reform. Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2026, Provisions related to the pharmaceutical industry. S. 891: Bipartisan Health Care Act (including section 227 - Modernizing and Ensuring PBM Accountability) S. 1302: Increasing Transparency in Generic Drug Applications Act S. 1414: Expedited Acccess to Biosimilars Act S. 1784: MAPS Act S. 1954: Biosimilar Red Tape Elimination Act H.R. 1: One Big Beautiful Bill Act H.R. 946: Orphan Cures Act H.R. 1492: Ensuring Pathways to Innovative Cures Act of 2025 or the EPIC Act of 2025 H.R. 2214: DRUG Act H.R. 4132: Prescription Information Modernization Act of 2025 HR 6283: Delinking Revenue from Unfair Gouging (DRUG) Act - bill aimed at reforming practices of Pharmacy Benefit Managers (PBMs) by delinking their revenue from the list price of prescription drugs Supporting Underserved and Strengthening Transparency, Accountability, and Integrity Now and for the Future (SUSTAIN) 340B Act (draft) Biopharmaceutical innovation policy issues User fee issues Vaccine policy issues Inflation Reduction Act of 2022 (P.L. 117-169) implementation policy issues Pharmacy Benefit Manager reform and policy issues Drug cost and pricing policy issues Drug importation policy issues Accelerated approval policy issues FDA policy issues Competition policy issues Orphan Drug Act policy issues Compounding policy issues Supply chain policy issues Clinical trial policy issues 340B drug discount program rebate and policy issues Patient assistance program policy issues Biosimilar approval and reimbursement policy issues Drug shortages policy issues  Artificial intelligence policy issues Executive Order, Delivering Most-Favored Nation Prescription Drug Pricing to American Patients Executive Order, Lowering Drug Prices by Once Again Putting Americans First

Client expense: $1,510,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE

H.R. 3178 / S. 1600, The Save Healthcare Workers Act, all provisions; H.R. 3266 / S. 1673, Mental Health Infrastructure Improvement Act, all provisions; H.R. 929 / S. 266, Dr. Lorna Breen Health Care Provider Protection Reauthorization Act, all provisions; H.R. 1585 / S. 709, Conrad State 30 and Physician Access Reauthorization Act, all provisions; Draft Bill, Healthcare Workforce Resilience Act, all provisions; Draft Bill, 340B PATIENTS Act, all provisions; H.R. 593, The Strengthening Pathways to Health Professions Act, all provisions; S.Res.230, A resolution supporting the goals and ideals of National Hospital Week, to be observed from May 11 through May 17, 2025, all provisions; Draft Bill , The Pharmaceutical Supply Chain Risk Assessment Act of 2023, all provisions; S. 1784 / H.R. 4191, The Mapping America's Pharmaceutical Supply (MAPS) Act, all provisions; S. 229 / H.R. 3789, Drug Price Transparency for Consumer (DTC) Act, all provisions; S. 2062, Rapid Reserve Act, all provisions; Draft Bill, Medical Debt Prevention and Relief Act of 2025, all provisions; S. 1929, SEPSIS Act, all provisions; H.R. 2483, SUPPORT for Patients and Communities Reauthorization Act of 2025, all provisions; S. 547, Train More Nurses Act, all provisions; Draft Bill, Issues pertaining to organ donations; Federal Emergency Management Agency (FEMA), RFI; The FEMA public assistance program; U.S. Department of Justice & Federal Trade Commission, Anticompetitive Deregulations, Recommendations for addressing regulations that foster anticompetitive conduct by insurers and limit the ability of hospitals and health systems to thrive in a competitive free market, among others; U.S. Department of Health and Human Services, Request for Information: Deregulation, Comments on how to eliminate burdensome and wasteful administrative requirements for hospitals and health systems; Enhanced Premium Tax Credits, Extension of Enhanced Premium Tax Credits; Rural Health Care Access, Issues to protect access to rural health care; 340B Program, Issues pertaining to protecting 340B Program; Maternal and Child Health, Access to maternal and child health care and addressing related workforce shortages, conditions of participation (COP), funding priorities; Behavioral Health, Issues related to expanding access to care and reducing regulatory barriers; Workforce, Nurse staffing mandate, workforce development programs; Health Care Resiliency & Preparedness, Issues pertaining to natural disasters, cyberattacks, and securing supply chains; Post-Acute Care, Issues pertaining to expanding patients' access to crucial services provided by Long-term care hospitals, inpatient rehabilitation facilities, skilled nursing facilities, and home health agencies; Health Plan Accountability, Issues specific to prior authorization, patient access to care, adequate provider networks, inappropriate denials, reducing account receivables, prompt pay; Rural Emergency Hospital designation, Issues pertaining to eligibility and payment rates for the Rural Emergency Hospital designation; Tax-exempt status, Issues pertaining to not-for-profit hospitals' tax exempt status and tax-exempt private activity bonds; Health Care Access, Issues pertaining to protecting patients access to the health insurance marketplaces; Price Transparency, Issues related to hospital price transparency.

Client expense: $6,150,000 · Firm income: Not reported

Government targets: Federal Emergency Management Agency (FEMA), Federal Trade Commission (FTC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Justice, Dept of (DOJ), SENATE

340B Drug Pricing Program - Continued to urge action to ensure covered entities have access to 340B discounted prices through contract pharmacies. Highlighted critical importance of the 340B program for hospitals. Children's Hospital Graduate Medical Education (CHGME) - Continued to urge Congress to increase funding for and reauthorize the CHGME program Drug shortages - Supported elements to increase transparency in prescription drug supply chain and increase reimbursement for generic prescription drugs; issues related to compounding; issues related to buffer inventory. Encouraged improved stakeholder communication and increased notification by manufacturers for a surges in demand Endorsed passage of the Drug Competition Enhancement Act (S.1040) Endorsed passage of the Affordable Prescriptions for Patients Act (S.1041) Endorsed passage of the Save Healthcare Workers Act (H.R.3178/S.1600) Endorsed passage of the Mapping Americas Pharmaceutical Supply (MAPS) Act (H.R.4191/S.1784) Hospital Group Purchasing - Advocated to highlight the value that hospital group purchasing organizations provide to hospitals and suppliers. Provided education on how GPOs work in the healthcare supply chain and the role they play in delivering value to healthcare providers, as well as key differences between traditional GPOs and PBMs. H.R 1 - Monitored development of the One Big Beautiful Bill Mental and Behavioral Health - Highlighted the need for legislation to address significant challenges to mental and behavioral health treatment, including increased demand for services, limited access to treatment, and clinician shortages. Non-medical drivers of health outcomes - Encouraged Congress and agencies to ensure tools like the Vizient Vulnerability Index are being utilized to understand data about disparities in health. Highlighted opportunities for the increased use of secondary health data in a clinical setting. Payer-mandated White Bagging - Urged support for policy updates related to payer-mandated white bagging for medications. Request for Public Comments on Section 232 National Security Investigation of Imports of Pharmaceuticals and Pharmaceutical Ingredients - Offered recommendations on the importance of considering incentives to support domestic manufacturing and financial support to providers Rural healthcare - Advocated for policies and initiatives that address the challenges of rural communities by promoting access to care and strengthening healthcare infrastructure Telehealth - Continued to advocate for the adoption of permanent telehealth policies to extend flexibilities beyond the current expiration date. Telemedicine prescribing - Encouraged DEA to finalize a telemedicine prescribing framework that is more similar to the flexibilities that have been in place since the COVID-19 PHE United States Core Data for Interoperability Draft Version 6 - Offer recommendations to constructively improve Draft USCDI v6, including additional requesting clarification on several data elements Workforce - Advocated for strengthening the health workforce through policies that support education, training, recruitment, and retention efforts

Client expense: $360,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), Commerce, Dept of (DOC), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act. (identical legislation)

Client expense: $380,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE

Administrations activities related to supply chain and domestic capacity; Department of Defense activities related to pharmaceutical and medical countermeasure supply chain for the warfighter; S.1784, Mapping America's Pharmaceutical Supply (MAPS) Act, provisions related to the improvement of coordination of Federal efforts to identify and mitigate health and national security risks; S.2062, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act, provisions related to improving supply chain resiliency for critical drug products with vulnerable supply chains; H.R.3966, Rolling Active Pharmaceutical Ingredient and Drug Reserve (RAPID Reserve) Act. (identical legislation)

Client expense: $380,000 · Firm income: Not reported

Government targets: Defense, Dept of (DOD), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Natl Security Council (NSC), SENATE